Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: A post hoc analysis of 4 randomized, placebo-controlled clinical trials

Journal of Clinical Psychiatry

Volumn 68, Issue 5, 2007, Pages 662-668

  Marder, Stephen R ^a,e   West, Britt ^b   Lau, Gina S ^c   Pultz, Joseph A ^c   Pikalov, Andrei ^d   Marcus, Ronald N ^c   Gutierrez Esteinou, Rolando ^c   Crandall, David T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Bristol Myers Squibb   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; LORAZEPAM; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; AGITATION; AKATHISIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; ADULT; FEMALE; HOSPITALIZATION; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RESTLESSNESS; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOMOTOR AGITATION; QUINOLONES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34249729541     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0503     Document Type: Article

References (36)

1. Pilowski LS, Ring H, Shine PJ, et al. Rapid tranquilization: a survey of emergency prescribing in a general psychiatric hospital. Br J Psychiatry 1992;160:831-835
2. Kunik ME, Yudofsky SC, Silver JM, et al. Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994:55(suppl):13-17
3. Yudofski SC, Silver JM, Hales RE. Treatment of agitation and aggression. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1998:881-900
4. San L, Arranz B, Escobar R. Pharmacological management of acutely agitated schizophrenic patients. Curr Pharm Des 2005;11:2471-2477
5. Cardoso CS, Caiaffa WT, Bandeira M, et al. Factors associated with low quality of life in schizophrenia. Cad Saude Publica 2005;21: 1338-1340
6. Mendelowitz AJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry 2004; 16:145-154
7. Battaglia J. Pharmacological management of acute agitation. Drugs 2005:65:1207-1222
8. Volavka J, Laska E, Baker S, et al. History of violent behavior and schizophrenia in different cultures: analyses based on the WHO study on Determinants of Outcome of Severe Mental Disorders. Br J Psychiatry 1997;171:9-14
9. Nolan KA, Volavka J, Czobor P, et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J Psychiatr Res 2005;39:109-115
10. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005;187:9-20
11. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-1151
12. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled, dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-448
13. Brook S, Luccy JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000;61:933-941
14. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001;155: 128-134
15. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-18
16. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62: 153-157
17. Yokka F, Marcus R, Oren D, et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study [poster]. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
18. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389
19. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-140
20. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45-53
21. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411
22. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
23. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
24. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136
25. Cutler AJ, Marcus RN, Hardy SA, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectrum 2006;11:691-702
26. Mintzer J (chairperson). Atypical antipsychotics: treatment of agitation across mental disorders. Symposium #34. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
27. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
28. Kinon BJ, Ahl J, Rotelli MD, et al. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med 2004;22:181-186
29. Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003;23:342-348
30. Meehan K, Zhang F, David S, et al,. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-397
31. DeQuardo JR. Worsened agitation with aripiprazole: adverse effects of dopamine partial agonism? [letter]. J Clin Psychiatry 2004;65:132-133
32. Dillenschneider A, Marcus R, Kostic D. Short and long-term effects of aripiprazole treatment on the excitement/hostility symptoms of schizophrenia [poster]. Presented at the 24th congress of the Collegium Internationale Neuro-Psychopharmacologicum; June 20-24, 2004; Paris, France
33. Volavka J, Czobor P, Citrome L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry 2005;66:1362-1366
34. Chengappa KN, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003;25:530-541
35. Kinon BJ, Roychowdhury SM, Milton DR, et al. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001; 62(suppl 2):17-21
36. Pajonk FG, Schreiner A, Peters S, et al. An open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. J Clin Psychopharmacol 2005; 25:293-300